Showing 3581-3590 of 4764 results for "".
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approachhttps://practicaldermatology.com/news/new-psa-guidelines-from-national-psoriasis-and-rheumatology-orgs-recommend-treat-to-target-approach/2457490/Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approach for all patients with active PsA. What’s more, the guidelines co
- Crown Laboratories Acquires Select Healthcare Brands from GlaxoSmithKlinehttps://practicaldermatology.com/news/crown-laboratories-acquires-select-healthcare-brands-from-glaxosmithkline/2457492/Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, De
- LEO, PellePharm Form Collaboration Focused on Innovationhttps://practicaldermatology.com/news/leo-pellepharm-form-collaboration-focused-on-innovation/2457501/A new strategic development and commercialization collaboration between LEO Pharma and PellePharm is intended to address unmet medical needs across various skin diseases with no approved treatments, the parties say. The collaborators seek to advance innovation and access to potential therapies fo
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- HintMD Launches Medical-Grade Skincare Subscriptionshttps://practicaldermatology.com/news/hintmd-launches-medical-grade-skincare-subscriptions/2457508/Medical-grade skincare subscriptions are now available through HintMD's platform. HintMD’s patent-pending software allows physicians, such as plastic surgeons and dermatologists, to turn any treatment plan into a monthly subscription payment for their patients. Skincare subscriptions al
- PRP Improves Skin Tone, Wrinkleshttps://practicaldermatology.com/news/prp-improves-skin-tone-wrinkles/2457511/Platelet-rich plasma (PRP) reduces the signs of aging on the face, according to the first randomized study of PRP. In the trial, 19 participants received PRP injections to one side of their face and a sham treatment with a saline solution to the other side. Six months afte
- Cutanea Life Sciences Launches Xepi Creamhttps://practicaldermatology.com/news/cutanea-life-sciences-launches-xepi-cream-1/2457512/Cutanea Life Sciences, Inc. has launched Xepi™ (ozenoxacin) Cream, 1% for the treatment of impetigo in adult and pediatric patients two months of age or older. Xepi is a non-fluorinated topical quinolone indicated for the treatment of impetigo due to Staphylococcus aureus
- The American Dermatological Association Is On Board with American Cancer Society's HPV Vaccine Policyhttps://practicaldermatology.com/news/the-american-dermatological-association-is-on-board-with-american-cancer-societys-hpv-vaccine-policy/2457513/The American Dermatological Association is co-sponsoring the American Cancer Society’s public policy of vaccination against Human Papillomavirus infections [HPV] beginning at age 11 or 12 for girls and boys. HPV is associated with protean medical illne
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second ca